Prostacyclin for Pulmonary Arterial Hypertension. This review demonstrates clinical and statistical benefit for intravenous prostacyclin. PubMed, Cochrane Database Syst Rev, 2019 May 1;5(5):CD012785. (Also see Scleroderma Treatments - General)
Real-life Experience of Inhaled Iloprost for Patients With Pulmonary Arterial Hypertension: Insights From the Spanish REHAP Registry. Data from the REHAP collected during 3 years shows that inh-ILO has low effectiveness independently of the treatment strategy used. PubMed, Int J Cardiol, 2019 Jan 15;275:158-164.
Acute and chronic effects of two different intravenous iloprost (ILO) regimens in systemic sclerosis: a pragmatic non–randomized trial. ILO had an acute effect as assessed by power Doppler US and by contrast, an ILO chronic effect was not detectable before the following infusion in both treatment groups. PubMed, Rheumatology (Oxford), 05/03/2018.
The safety of iloprost (ILO) in systemic sclerosis in a real–life experience. Our data suggest that calcium channel blockers should be transitorily stopped while using ILO and that a pre–treatment approach might reduce or control adverse events. PubMed, Clin Rheumatol, 02/22/2018.
Role of Vasodilator Testing in Pulmonary Hypertension (PAH). To identify patients who are likely to have a beneficial response to calcium channel blockers (CCBs) and therefore a better prognosis, acute vasodilator testing should be performed in patients in certain subsets of PAH. PubMed, Prog Cardiovasc Dis. (Also see Scleroderma Treatments - General)
Case Study: Possible anti–metastatic effect of Iloprost in a patient with systemic sclerosis (SSc) with lung cancer. Herein, we report iloprost treatment of a 60-year-old-woman with SSc, who lately developed pulmonary hypertension as a complication of her disease and lung adenocarcinoma as a co-incidence simultaneously. Yavuz Pehlivan, Reheumatology International. (Also see Cancer)
SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to: